Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.

导出原文传递

翻译打印收藏纠错

作者： Nele,Boeckx ^[1] ; Reija,Koukakis ^[2] ; Ken,Op de Beeck ^[1] ; Christian,Rolfo ^[3] ; Guy,Van Camp ^[4] ; Salvatore,Siena ^[5] ; Josep,Tabernero ^[6] ; Jean-Yves,Douillard ^[7] ; Thierry,André ^[8] ; Marc,Peeters ^[9]

作者单位： Center for Oncological Research, University of Antwerp, Wilrijk, Belgium; Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium. ^[1] Biostatistics, Amgen Ltd, Uxbridge, United Kingdom. ^[2] Center for Oncological Research, University of Antwerp, Wilrijk, Belgium; Department of Oncology, Antwerp University Hospital, Edegem, Belgium. ^[3] Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium. ^[4] Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano, Milan, Italy. ^[5] Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain. ^[6] Institut de Cancérologie de l'Ouest (ICO) René Gauducheau, Nantes, France. ^[7] Hôpital Saint Antoine, Sorbonne Universités, UPMC Paris 06 and GERCOR, Paris, France. ^[8] Center for Oncological Research, University of Antwerp, Wilrijk, Belgium; Department of Oncology, Antwerp University Hospital, Edegem, Belgium. Electronic address: marc.peeters@uza.be. ^[9]

关键词 RAS WT RAS mutant Treatment lines Tumor location mCRC